Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .
Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial.
The objective was to determine the effect of metformin on the concentrations of resistin and other markers of insulin resistance or inflammation ( C-reactive protein , cytokines , body weight , HbA1c , among others ) in minors with glucose intolerance . Patients aged 4 to 17 years with glucose intolerance were studied . They were r and omized to receive 850 mg of either metformin or placebo twice daily for 12 weeks , during which all followed an iso-caloric diet and an exercise program .  High sensitivity C-reactive protein , TNF-alpha , IL-6 , IL1-beta , resistin , leptin , adiponectin , glucose , insulin , HbA1c , lipid profile and transaminases were measured at the beginning and at the end of the period . Fifty-two patients were included , 11.9±2.6 years old ; 28 ( 12 males/16 females ) received metformin and 24 placebo ( 11 males/13 females ) . Baseline characteristics were similar between groups ( except for body mass index , which in the metformin group was slightly higher ) . Percentage weight loss was greater in the metformin group ( -5.86 % vs 2.75 % , P<.05 ) . At study end , there were statistically significant differences in resistin concentrations , even after adjusting for confounding variables ( F=7.714 ; P<.006 ) . Also , metformin was associated with a significant decrease in HOMA-IR index ( P=.032 ) and HbA1c levels ( P=.001 ) , but no change was observed in the concentration of other markers of inflammation . Metformin result ed in significant reductions of plasma resistin levels in minors with glucose intolerance . This change is independent of its effects on body weight . In contrast , metformin did not alter the concentration of inflammatory markers
Network meta- analysis revealed that in adolescents , intervention with 2000 mg/day metformin ranked better than other interventions ; however , 1000 mg/day metformin for 3 months may be most suitable for adolescents .
For adults , metformin at doses of 3000 and 1000 mg/day ranked the highest , other than minimeal and lifestyle interventions ; moreover , intervention with 3000 mg/day for 6 months and 1000 mg/day for 0.5 months may be suitable for adults .
Conclusion When considering the efficacy of interventions for losing weight , metformin offers clear advantages for overweight and obese population
Purpose Our aim was to assess the efficacy of metformin for weight loss in overweight and obese people through a systematic review and network meta- analysis and to identify the most suitable dosage and intervention period for using metformin  in adolescents and adults .